Portfolio
United States
Aviva Systems Biology (ASB) is a leading provider of high-quality antibodies and immunoassay kits, supporting scientists in their basic research, preclinical, drug development, and diagnostics workflows. Founded by Progressive Group in 2001 and later co-invested by Progressive Venture Partners and the prominent National Material L.P., ASB benefits from strong backing and industry expertise. Read more on their company website.
Aviva Biosciences focused on developing innovative technologies for biomedical research and diagnostics, creating cutting-edge tools like the Sealchip and Redsift Cell Processor. Progressive Venture Partners co-founded the company in 1999 and later successfully co-invested with one of the largest Taiwanese institutional investors, CDIB Capital Group, to develop its technologies. In 2020, Aviva Biosciences was merged with Aviva Systems Biology, further consolidating its innovative assets.
GenWay Biotech specializes in providing comprehensive production and manufacturing services for the life sciences and diagnostic industries, maintaining ISO13485 accreditation for high standards in antibody and protein development. Aviva Systems Biology acquired GenWay Biotech in 2017. Read more on their company website.
InfraScan is an FDA-cleared, pioneering medical device company specializing in handheld diagnostic tools for detecting intracranial bleeding using near-infrared (NIR) technology. InfraScan has repeatedly received contracts and grants from the Department of Defense, Office of Naval Research, US Navy, US Marine Corps, and private investments. In 2017, Progressive Venture Partners joined its effort to continue expanding this lifesaving technology. Read more on their company website.
BandGrip is a pioneering medical device company focused on developing innovative wound closure solutions, using micro-anchors to securely close wounds, promoting quicker healing and reducing scarring. Progressive Venture Partners invested in the company in 2022. Read more on their company website.
China
Primus Medical Shanghai (PMS) is a leading in vitro diagnostic and medical device distribution company in China and a fully owned subsidiary of Progressive Venture Partners. PMS began with a focus on diagnostic products and has since expanded its portfolio to include a wide range of innovative medical solutions through our portfolio partnerships. The company operates indirect sales in every city and collaborates with numerous partners to manage sales channels effectively. With offices in Beijing, Shanghai, and Guangzhou, and a network of over 80 national distributors, Primus provides comprehensive market coverage and support throughout all 31 provinces, autonomous regions, and municipalities. Read more on their company website.
Aviva Beijing is a subsidiary of Aviva Systems Biology, focusing on providing high-quality antibodies and immunoassay kits to support scientists in their basic research, preclinical, drug development, and diagnostic workflows. Leveraging advanced technologies and a strong R&D team, Aviva Beijing is committed to delivering innovative solutions that meet the needs of the scientific community in China. Read more on their company website.
Shanghai United Cell Biotechnology Co. Ltd. (SUCB) is a pharmaceutical company specializing in the production of therapeutic peptides and proteins. They currently offer two therapeutic hormones and a vaccine in China. In 2004, Progressive Venture Partners invested in SUCB alongside Singaporean state-owned conglomerate Temasek Holdings Limited and the largest pharmaceutical company in ASEAN, UNILAB, to support its growth and development. In 2021, Hillhouse Investment bought out all the shares, leading to Progressive Venture Partners’ successful exit from SUCB. Read more on their company website.
Senxu Medical specializes in advanced laboratory management solutions, utilizing AI technology to ensure diagnostic quality and outcomes. Their patient-based real-time quality control (PBRTQC) systems and AI-driven products enhance diagnostic accuracy and laboratory efficiency. In 2024, Progressive Venture Partners invested in Senxu Medical to support and expand their groundbreaking innovations. Read more on their company website.
Taiwan
Progressive Group is a leading in vitro diagnostic and medical device distribution company dedicated to providing high-quality diagnostic and medical device to healthcare market in Taiwan. As a fully owned subsidiary of Progressive Venture Partners, Progressive Group leverages a robust network and extensive experience in the healthcare industry to ensure that innovative medical solutions are accessible to patients who need them. Our expertise in product registration, regulatory compliance, market access, TFDA reimbursement application, market penetration and distribution enables us to deliver reliable and effective healthcare products in highly efficient manner. By having a dedicated and proven record sales team operating in every major hospital in Taiwan, we ensure direct access to our advanced medical solutions. Read more on their company website.
Transwell specializes in developing regenerative cell therapy products, including cells, culture media, and exosome products, to regenerate tissue and promote wound healing. In 2020, Progressive Venture Partners invested and joined efforts to continue advancing this innovative technology. Read more on their company website.
Life Fusion Inc. specializes in high-purity medical-grade collagen extraction for advanced infusion care solutions for wound care, with its technology also extended to aesthetic medicine and health supplements. In 2021, Progressive Venture Partners invested and partnered with Life Fusion to advance the development of these innovative technologies. Read more on their company website.
Weizhou is a company specializing in advanced wound care products, including the Weizhou Hydrophilic Wound Dressing. This innovative product utilizes plant stem cell extracts and Dragon's Blood extracts to enhance healing and improve tissue swelling and bruises. In 2020, Progressive Venture Partners co-founded Weizhou to further develop these technologies.